Skip to content

Insmed INSM Market capitalization

Market capitalization at other companies

United Therapeutics logo
United TherapeuticsUTHR
$25.99B+87.7%
Incyte logo
IncyteINCY
$18.73B+59.9%
Amgen logo
AmgenAMGN
$189.67B+13.3%
ALN
Alnylam PharmaceuticalsALNY
$43.88B+25.6%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$13.22B+19.9%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$588.76B+47.3%

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Enterprise value$21.34B+142%
P/S26×+4.1×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Computed from the period-end share price: $35.25B.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's market capitalization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's market capitalization?
Insmed (INSM) reported market capitalization of $35.25B in Q1 2026.
How has Insmed's market capitalization changed year-over-year?
Insmed's market capitalization increased by 155.3% year-over-year, from $13.81B to $35.25B.
What is the long-term trend for Insmed's market capitalization?
Over 4 years (2021 to 2025), Insmed's market capitalization has grown at a 65.4% compound annual growth rate (CAGR), from $13.55B to $101.48B.
What does market capitalization mean?
What the stock market says the company's equity is worth.
How do you interpret market capitalization?
A size and market-sentiment gauge, not a quality measure — interpret through valuation ratios (P/E, P/S) that relate it to fundamentals.
How does market capitalization compare across companies?
Comparable across companies as a size class; the input to every equity-price valuation multiple.